Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.
Telesta Therapeutics announced that the company will not start another Phase III clinical trial on its own of MCNA, a drug for high-risk, non-muscle invasive bladder cancer patients.
2016 Annual Report: Top 10 Pipelines
"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemiaThe pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
GSK’s Nucala® (mepolizumab) receives approval from US FDA Issued: London UK – LSE Announcement First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype GlaxoSmithKline plc […]
Rumors Confirmed, Pfizer and Allergan In Talks to Merge
Biologics License Application (BLA), Biosimilars, Central Nervous System, CNS, Deals, Deals, FDA, FDA/Regulatory, Gastrointestinal, Gastrointestinal Diseases, Gastrointestinal Disorders, Generics, Health, M&A, M&A, Market Cap, Rumors, Tax Savings, TherapeuticsAfter months of speculation on who Pfizer Inc. (PFE) will attempt to buy are now officially over — sort of. It has been confirmed that Pfizer Inc. and Allergan Plc […]
FDA approves Amgen’s injected immunotherapy for melanoma
Analysts, Approvals, Biologics License Application (BLA), Biotech, Biotechnology, Clinical Trials, FDA, FDA/Regulatory, Forecasts, Health, Herpes, Herpes Simplex Virus, Immune System, Immune Systems, Immunotherapies, Immunotherapy, Melanoma, Melanoma Lesions, Pricing, R&D, Shares, Shares, Studies, Viral Therapy, Wall Street, Warning LabelingU.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns […]
FDA Approves Praxbind (idarucizumab), Specific Reversal Agent for Pradaxa (dabigatran etexilate mesylate)
Accelerated Drug Approvals, Anticoagulants, Approvals, Biologics License Application (BLA), Bleeding, Breakthrough Therapy Designation, FDA, FDA/Regulatory, First-In-Class, Health, Priority Review, R&D, TherapeuticsRIDGEFIELD, Conn., Oct. 16, 2015 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) granted approval of Praxbind® (idarucizumab). PRAXBIND is indicated for patients treated […]
Thousand Oaks, Calif.-based Amgen (AMGN), faced with generic and biosimilars competition as its blockbusters lose patent protection, is fighting back on a number of fronts. On Oct. 2, 2015, […]